title: Hypothesis: antiplatelet effects of selective serotonin reuptake inhibitors cause clinical benefits on cardiovascular disease and increase risks of bleeding.
authors.affiliation: HeartDrug Research Laboratories, Johns Hopkins University, Baltimore, MD 21204, USA. heartdrug@aol.com
authors.forename: Victor L
authors.initials: VL
authors.lastname: Serebruany
authors.forename: Christopher M
authors.initials: CM
authors.lastname: O'Connor
authors.forename: Ranga R
authors.initials: RR
authors.lastname: Krishnan
authors.forename: Charles H
authors.initials: CH
authors.lastname: Hennekens
mesh_terms: D002318:Cardiovascular Diseases / Q000188:drug therapy*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D010975:Platelet Aggregation Inhibitors; D017367:Selective Serotonin Reuptake Inhibitors